Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

W81XWH-22-KCRP-CTA: DoD Kidney Cancer, Clinical Trial Award

Closed Closed October 20, 2022 Opportunity W81XWH-22-KCRP-CTA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2022.

• Total funding$8.0 million
• Expected awards3
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The KCRP Clinical Trial Award supports the rapid implementation of early-phase clinical trials (phase 0, phase 1, phase 1/2) with the potential to have a significant impact on the treatment or management of kidney cancer. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, surgical procedures, behavior modifications, clinical guidance, and/or emerging approaches and technologies. Therapeutic approaches testing existing interventions for new indications in kidney cancer are also encouraged. It is anticipated that outcomes from studies funded by this award will provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform kidney cancer patient care. Funding from this award mechanism must support a clinical trial. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Subject Resource Document is provided at https://cdmrp.army.mil/pubs/pdf/ Human%20Subjects%20Resource%20Document.pdf. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other FY22 KCRP program announcements being offered. Cell Therapy Focus Option (New for FY22): The FY22 KCRP Clinical Trial Award may support cell therapy clinical trials. Such studies may require additional resources due to required optimization of cell therapy manufacturing or clinical trial correlative studies. Applicants may request higher levels of funding within the defined period of performance. The application must demonstrate access to the necessary specimens and/or data of the proposed cohort. Appropriate access must be confirmed at the time of application submission. Qualified Collaboration Option (New for FY22): The KCRP will offer a Qualified Collaboration Option to encourage leveraging of existing infrastructure previously funded.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.